Exciting news! CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001. They have dosed the first patient with sickle cell Disease. To find more about this research, ask your doctor. More hope is on the horizon! Read the press release to learn more.